Grünenthal GmbH, a pharmaceutical company focusing on pain management and related diseases, has appointed Uli Brödl as chief scientific officer and a member of the corporate executive board. Dr Brödl joins Grünenthal from Boehringer Ingelheim where he served as head of global clinical development & operations, and was a member of the company’s venture fund investment committee. Earlier, he led Boehringer’s Canadian medical organisation and founded and co-chaired the BI Canada Incubator, an innovation lab. Dr Brödl is a doctor of medicine from Ludwig-Maximilians University Munich, Germany and is an adjunct professor of internal medicine at the university.
Grünenthal announced the appointment on 9 January 2025.
Copyright 2025 Evernow Publishing Ltd.